Anika Therapeutics (ANIK) risk factors, FY2024 10-K

Risks Related to Our Business and Industry

1. 01Our financial performance depends on sales growth and increasing demand for our product portfolios, and we may not be able to successfully manage the current, and future, expansion of our operations
2. 02Maintain the financial, accounting, and management systems needed to manage our growing business and the associated demand for our products
3. 03Substantial competition could materially affect our financial performance
4. 04Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if we are excluded from being a supplier by a group purchasing organization or similar entity
5. 05A significant portion of our OA Pain Management revenues are derived from a small number of customers, the loss of which could materially adversely affect our business, financial condition and results of operations
6. 06We experience quarterly sales volume variation, which makes our future results difficult to predict and makes period-to-period comparisons potentially not meaningful
7. 07We rely on a small number of suppliers for certain key raw materials and components for the manufacturing and delivery of our products, and disruption could materially adversely affect our business, financial condition, and results of operations
8. 08Our manufacturing processes involve inherent risks, and disruption could materially adversely affect our business, financial condition, and results of operations
9. 09We could become subject to product liability claims, which, if successful, could materially adversely affect our business, financial condition, and results of operations
10. 10We are increasingly dependent on sophisticated information technology and if we fail to effectively maintain or protect our information systems or data, including from data security incidents or breaches, our business could be adversely affected
11. 11We may face circumstances in the future that will result in impairment charges, including, but not limited to, goodwill impairment, intangible assets impairment and in-process research and development charges
12. 12Our business is dependent upon hiring and retaining qualified management, operations and technical personnel
13. 13We may require additional capital in the future. We cannot give any assurance that such capital will be available at all or on terms acceptable to us, and if it is available, additional capital raised by us could dilute your ownership interest or the value of your shares
14. 14Further expanding our business in international markets
15. 15Changes in tax law could adversely affect our business and financial condition
16. 16The impact of the Russian invasion of Ukraine and the conflict in the Middle East on the global economy, energy supplies and raw materials is uncertain, but may prove to negatively impact our business and operations
17. 17The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax and other federal policies that may adversely affect our business

Risks Related to Our Commercialization Activities

1. 18Our license agreements with J&J MedTech provide substantial control of Monovisc and Orthovisc in the United States to J&J MedTech and J&J MedTech’s actions could have a material impact on our business, financial condition and results of operations
2. 19We may not succeed in our buildout of our direct sales channel in the United States, and our failure to do so could negatively impact our business and financial results
3. 20We are dependent upon marketing and distribution partners and the failure to maintain strategic alliances on acceptable terms will have a material adverse effect on our business, financial condition, and results of operations
4. 21Sales of our products are largely dependent upon third-party health insurance coverage and reimbursement and our performance may be harmed by health care cost containment initiatives or decisions of individual third-party payers

Risks Related to Our Product Development and Regulatory Compliance

1. 22We are facing a longer than expected pathway to commercialize our Cingal product in the United States, and we may face other unforeseen difficulties in achieving regulatory approval for Cingal and Hyalofast, which could affect our business and financial results
2. 23Failure to obtain, or any delay in obtaining, FDA or other U.S. and foreign governmental clearances or approvals for our products may have a material adverse effect on our business, financial condition, and results of operations
3. 24Once obtained, we cannot guarantee that the FDA or international product clearances or approvals will not be withdrawn or that relevant agencies will not require other corrective action, and any withdrawal or corrective action could materially affect our business and financial results
4. 25Our operations and products are subject to extensive regulation, compliance with which is costly and time consuming, and our failure to comply may result in substantial penalties, including recalls of our products
5. 26Any changes in the FDA or international regulations related to product approval or approval renewal, including those currently under consideration by the FDA or those that apply retroactively, could adversely affect our competitive position and materially affect our business and financial results
6. 27If we are found to have improperly promoted our products for off-label uses, we may become subject to significant fines and other liability
7. 28We are subject to various healthcare laws and regulations, and any failure to comply with applicable laws could subject us to significant liability and harm our business
8. 29We are subject to environmental regulations and any failure to comply with applicable laws could subject us to significant liabilities and harm our business

Risks Related to Our Growth Initiatives

1. 30We may have difficulty managing our growth
2. 31We may not generate the expected benefits of our acquisitions, and the actions associated with the divestiture of those acquisitions could disrupt our ongoing business, distract our management and increase our expenses
3. 32We expect to continue to actively explore inorganic growth as a part of our future growth strategy, which exposes us to a variety of risks that could adversely affect our business operations
4. 33Customer and employee uncertainty about the effects of any acquisitions or divestitures could harm us
5. 34As our international sales and operations grow, we could become increasingly subject to additional economic, political, and other risks that could harm our business
6. 35Burdens of complying with a wide variety of foreign laws, including the EU MDR and GDPR among others

Risks Related to Our Intellectual Property

1. 36We may be unable to adequately protect our intellectual property rights, which could have a material impact on our business and future financial results
2. 37There can be no assurance that we will not infringe upon the intellectual property rights of others, which could have a significant impact on our business and financial results

Risks Related to Ownership of Our Common Stock

1. 38Our stock price may be highly volatile, and we cannot assure you that market making in our common stock will continue
2. 39Our charter documents contain anti-takeover provisions that may prevent or delay an acquisition of our company
3. 40If securities or industry analysts do not publish or cease publishing research or reports about us, our business, or our market, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could decline
4. 41We have been, and may continue to be, subject to the actions of activist stockholders, which could cause us to incur substantial costs, divert management’s and the board’s attention and resources, and have an adverse effect on our business and stock price